Canaccord analyst Jason Mills reiterated a Hold rating on AngioDynamics and raised his price target to $20 following the company's "fairly in-line" quarter, telling investors in a research note that lack of upside, along with a "somewhat lackluster" guide for FY19 drove a sell-off in the stock post print. While Mills thinks the company is better positioned operationally today than it was two years ago when CEO Clemmer took over the helm, growth remains the key piece missing from the story. The analyst believes NanoKnife is the company's biggest opportunity and potential growth driver, but thinks it will be a few years before it can provide meaningful contributions to AngioDynamics' top line.